跳转至内容
Merck
CN
  • Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.

Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.

Bioorganic & medicinal chemistry letters (2010-08-31)
Wilna J Moree, Bin-Feng Li, Said Zamani-Kord, Jinghua Yu, Timothy Coon, Charles Huang, Dragan Marinkovic, Fabio C Tucci, Siobhan Malany, Margaret J Bradbury, Lisa M Hernandez, Jianyun Wen, Hua Wang, Samuel R J Hoare, Robert E Petroski, Kayvon Jalali, Chun Yang, Aida Sacaan, Ajay Madan, Paul D Crowe, Graham Beaton
摘要

Analogs of the known H(1)-antihistamine R-dimethindene with suitable selectivity for key GPCRs, P450 enzymes and hERG channel were assessed for metabolism profile and in vivo properties. Several analogs were determined to exhibit diverse metabolism. One of these compounds, 10a, showed equivalent efficacy in a rat EEG/EMG model to a previously identified clinical candidate and a potentially superior pharmacokinetic profile as determined from a human microdose study.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
茚, ≥99%
Sigma-Aldrich
茚, 98%
Dimetindene maleate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
茚, contains 50-100 ppm tert-butylcatechol as stabilizer, technical grade, ≥90%